ZUBSOLV Growth in Key Segment
ZUBSOLV showed stabilization in demand with growth in the Commercial segment year-over-year and quarter-over-quarter. The Commercial segment grew by 22% from the previous year, which is significant for profitability since it's more profitable than Medicaid and Medicare segments.
Successful Human Factor Study for OX124
Orexo completed a new Human Factor study for OX124, which was successful in addressing issues raised by the FDA regarding instructions for use.
AmorphOX Platform Opportunities
The AmorphOX platform has continued to show potential with ongoing feasibility projects in various chemical structures, including vaccines and biologics, indicating a stable formulation across small molecules and peptides.
Positive EBITDA Outlook
Orexo maintained a high gross margin of 86% and expects to achieve a positive EBITDA for the full year, despite current challenges.